Association between donor T-cell chimerism status at day 28 and subsequent complete remissions of the underlying malignancies
T-cell chimerism, % . | No. of patients with complete remissions/no. patients at risk (%) . |
|---|---|
| 0-50 | 3/15 (20) |
| 51-75 | 13/26 (50) |
| 75-90 | 9/20 (45) |
| 90-100 | 5/11 (45) |
T-cell chimerism, % . | No. of patients with complete remissions/no. patients at risk (%) . |
|---|---|
| 0-50 | 3/15 (20) |
| 51-75 | 13/26 (50) |
| 75-90 | 9/20 (45) |
| 90-100 | 5/11 (45) |
Analysis restricted to patients alive and without complete responses by day 28.
*P value (P = .16) obtained from trend test in a Cox regression model adjusting for presence of indolent disease, use of fludarabine, and use of an unrelated donor.